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Dendritic cells (DCs) are critically involved in inducing either immunity or tolerance. During the last decades efforts
have been devoted to the development of ad hoc methods to manipulate DCs in vitro to enhance or stabilize their
tolerogenic properties. Addition of IL-10 during monocyte-derived DC differentiation allows the induction of DC-10,
a subset of human tolerogenic DCs characterized by high IL-10/IL-12 ratio and co-expression of high levels of the
tolerogenic molecules HLA-G and immunoglobulin-like transcript 4. DC-10 are potent inducers of adaptive type 1
regulatory T cells, well known to promote and maintain peripheral tolerance. In this review we provide an in-depth
comparison of the phenotype and mechanisms of suppression mediated by DC-10 and other known regulatory
antigen-presenting cells currently under clinical development. We discuss the clinical therapeutic application of
DC-10 as inducers of type 1 regulatory T cells for tailoring regulatory T-cell-based cell therapy, and the use of DC-10
as adoptive cell therapy for promoting and restoring tolerance in T-cell-mediated diseases.
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Dendritic cells (DCs) are potent antigen-presenting cells
(APCs) that possess the ability to stimulate naïve T cells
[1]. They represent an essential link between innate and
adaptive immunity and are widely distributed in all tis-
sues, especially in those that provide an environmental
interface. DCs develop from bone marrow progenitors
and circulate in the bloodstream as immature precursors
prior to migration into peripheral tissues. DCs patrol the
extracellular milieu, and uptake and process antigens
(Ags), subsequently presenting them on the cell surface
in complex with major histocompatibility molecules.
Upon appropriate stimulation, DCs undergo maturation
and migrate to secondary lymphoid organs where they
present Ags to T cells and prime adaptive immunity. In
the steady state, immature DCs migrate at low ratio to
the lymph nodes, without undergoing activation, where
they can thereby present Ags to T cells in the absence of
co-stimulation and induce clonal T-cell anergy [2] or
regulatory T cells (Tregs) [3].* Correspondence: gregori.silvia@hsr.it
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distribution, and reproduction in any mediumIt is generally accepted that DCs implicated in
tolerance are in a different state of activation and/or dif-
ferentiation. The microenvironment in which DCs reside
and are activated may affect their functions towards
tolerance rather than active immune response. However,
it has become evident that specialized subsets of DCs,
identified according to the expression of specific mar-
kers, promote and maintain tissue homeostasis and tol-
erance. One example are Langherans cells characterized
by the expression of langerin (CD207) and birbeck
granules [4,5], which represent a specialized subset of
immature DCs resident in the skin. It has been shown
that inflammatory stimuli can either promote the diffe-
rentiation of Langherans cells that initiate a productive
immune response or their recruitment as immature DCs
into the T-cell areas of lymph nodes where they contri-
bute to tolerance [4]. Another example of tolerogenic
DCs are that express CD103 reside in the lamina pro-
pria of the small intestine [6,7]. Similarly to murine
CD103+ DCs, [6,8,9], human CD103+ DCs isolated from
mesenteric lymph nodes have been shown to promote
Tregs and to control tissue homeostasis [4]. In addition,
a subset of plasmacytoid DCs co-expressing CD123
and CCR6 can be identified in draining lymph nodes
of melanoma-bearing patients [10]. These DCs areCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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3-dioxigenase (IDO) and have been shown to control
immune responses in vitro.
During the last decades, several molecules that modu-
late DC functions toward tolerance have been identified
[11], providing the possibility to exploit their use in vitro
for the generation of tolerogenic DCs. Different cyto-
kines have been used during differentiation or activation
of DCs, such as TNFα [12,13], granulocyte–macrophage
colony-stimulating factor (GM-CSF) [14], granulocyte
colony-stimulating factor (G-CSF) [15,16], macrophage
colony-stimulating factor (M-CSF) [17], hepatocyte
growth factor (HGF) [18], IL-10 alone [19-21] or in com-
bination with transforming growth factor beta (TGFβ)
[22]. Alternatively, pharmacological mediators, including
1,25-dihydroxyvitamin D3 [23,24], glucocorticoids [25],
prostaglandin E2 [26-28], or immunosuppressive drugs
such as cyclosporine [29], tacrolimus [30], mycophenolate
mofetil [31] or rapamycin (RAPA) [32,33] modulate DCs.
Tolerogenic DCs can be also generated by culturing
monocyte-derived DCs with ligands for immunoglobulin-
like transcripts (ILTs; that is, the nonclassical HLA-G
molecule [34]), or cobalt protoporphyrin, an inducer of
heme oxygenase-1 (HO-1) [35]. Finally, advances in gene-
transfer technology offer the possibility to genetically
manipulate DCs to endow their tolerogenic potential by
overexpressing immunosuppressive molecules such as
cytotoxic T-lymphocyte antigen 4, IDO, or IL-10 [11].
The aforementioned strategies target DC differenti-
ation and/or activation and inhibit IL-12 production,
thereby limiting the capacity of DCs to prime and/or
activate effector T cells. Some of these treatments are
also able to promote the upregulation of tolerogenic
molecules such as ILTs, IDO, and HO-1, or the secretion
of immunomodulatory cytokines, all of which are im-
portant for the induction and/or activation of Tregs.
Tregs are specialized subsets of T cells involved in pro-
moting and maintaining immune tolerance via their ability
to control responses to self and foreign Ags. Over the
years, several types of Tregs have been identified but, to
date, the best characterized are the forkhead box P3
(FOXP3)-expressing regulatory T cells (FOXP3+ Tregs)
[36] and the CD4+ IL-10-producing type 1 regulatory T
(Tr1) cells [37]. FOXP3+ Tregs can be either naturally oc-
curring which are selected in the thymus, or adaptive [38].
Tr1 cells can be induced in the periphery upon chronic
Ag stimulation in the presence of IL-10 [39], and are cur-
rently identified by their unique cytokine profile consisting
of high levels of IL-10, TGFβ, low levels of IL-2 and vari-
able amounts of IFNγ, in the absence of IL-4 [37,40].
Depending on the agent used for tolerogenic DC induc-
tion, the resulting DCs are equipped with defined tolero-
genic molecules, which determine their ability to
promote either FOXP3+ Tregs or Tr1 cells [41].In this review we will discuss the role of IL-10 in the
induction of human tolerogenic DCs focusing our atten-
tion on a subset of tolerogenic DCs, termed DC-10,
identified and characterized by our group [21]. The
major characteristics of these cells will be compared
with those of other tolerogenic APCs currently under
clinical development. Foreseen clinical applications of
DC-10 will be also discussed.
IL-10 and modulation of dendritic cells
IL-10 is an immune-modulatory cytokine that plays a
central role in controlling inflammation, inhibiting im-
mune responses, and inducing tolerance [42]. IL-10
downregulates the expression of major histocompatibi-
lity complex class II and co-stimulatory molecules,
CD80 and CD86, on DCs [43-45]. In addition, the re-
lease of IL-1β, IL-6, TNFα and, most markedly, IL-12 by
DCs is abolished after IL-10 treatment [42,46,47]. These
effects have been shown either when immature DCs are
exposed to IL-10 [48], or when DCs are matured in the
presence of IL-10 [19,20]. Importantly, IL-10-treated
DCs acquire the ability to induce anergic T cells [48]
with suppressive activity in vitro [19,20].
The tolerogenic effect of IL-10 on DCs is not simply
due to the inhibition of proinflammatory cytokine pro-
duction or of co-stimulatory molecule expression, but
also to the induction or the expression/overexpression
of tolerogenic molecules. IL-10 upregulates the produc-
tion of IL-10 itself [49], the expression of HLA-G [50],
of ILT2 and ILT4 [51], and of HO-1 [52,53] on DC pre-
cursors, rendering them regulatory cells capable of dam-
pening immune responses and of inducing Tregs.
In addition to preventing DC activation, IL-10 modu-
lates DC differentiation. The generation of CD1a+
human monocyte-derived DCs is impaired by the
addition of IL-10 throughout the culture, and the result-
ing cells display a macrophage-like cell phenotype [54].
Other studies reported that treatment of human mono-
cytes with IL-10 gives rise to a population of cells
expressing markers associated with DCs such as CD83
and BDCA-3 [55,56]. We recently developed a protocol
to efficiently differentiate a population of human tolero-
genic DCs, DC-10, by culturing human monocytes in
the presence of IL-10 (see next paragraph) [21].
DC-10 are a distinct population of human tolerogenic
dendritic cells
Our group set up a protocol for the in vitro differen-
tiation of human tolerogenic DCs, called DC-10, for
their ability to spontaneously secrete large amounts of
IL-10 [21]. DC-10 are differentiated from peripheral
blood monocytes cultured for 7 days in the presence of
GM-CSF, IL-4 plus IL-10 (Figure 1A). Resulting DC-10
are CD11c+CD11b+, express CD14 and CD16 but not
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myeloid phenotype, being CD83+, CD86+ and HLA-DR+.
Moreover, DC-10 express high levels of HLA-G and
of other signaling tolerogenic molecules ILT2, ILT3,
and ILT4 (Figure 1B). In addition to spontaneously
secrete high amounts of IL-10 (mean ± standard error
1.3 ± 0.3 ng/ml, n= 16; Figure 1C), DC-10 produce IL-6
(1.04 ± 0.2 ng/ml, n = 16), low levels of TNFα
(0.16± 0.08 ng/ml, n=16), and no IL-12. Importantly,
DC-10 are phenotypically and functionally stable since,
upon activation, they maintain their cytokine secretion
profile (high IL-10/IL-12 ratio; Figure 1C) and their
phenotype (S. Gregori and D. Tomasoni, personal com-
munication). Functional assays showed that although
















































Figure 1 Distinctive features of in vitro differentiated (tolerogenic) DC
monocytes are cultured for 7 days in the presence of granulocyte–macrop
express high levels of HLA-G and immunoglobulin-like transcript (ILT) 4. DC
expression of ILT2, ILT3, ILT4 and HLA-G. Percentages of immature dendriti
ILT4 and HLA-G (mean± standard error, n= 16) are shown. (C) Cytokine sec
panel) or stimulated with lipopolysaccharide and IFNγ (lower panel). Cultur
were measured by ELISA (mean± standard deviation, n= 16). As control, im
IL-4 for 7 days were used. *P< 0.05; **P< 0.005; ***P< 0.0005; ****P< 0.0001T cells, they induce the differentiation of anergic allo-
specific IL-10-producing Tr1 cells [21], even upon activation
(S. Gregori and D. Tomasoni, personal communication).
Comparative analysis demonstrated that DC-10 are
phenotypically different and more potent than immature
DCs [57] or IL-10-modulated mature DC (IL-10 DCs)
[20] to promote allo-specific Tr1 cells. Both immature
DCs and IL-10 DCs are indeed CD1a+CD14–, and ex-
press significantly lower levels of HLA-DR, CD80,
CD83, and CD86 than DC-10 [58]. Immature DCs spon-
taneously secrete low levels of IL-10, while both IL-10
DCs and DC-10 secrete high amounts of IL-10 [58].
Upon activation, both immature DCs and IL-10 DCs
produce significant amounts of IL-12 and TNFα, while
















-10. (A) Protocol for in vitro differentiation of DC-10. Peripheral blood
hage colony-stimulating factor (GM-CSF), IL-4 and IL-10. (B) DC-10
-10 were analyzed by flow cytometry to determine the levels of
c cells (DCs) and DC-10 expressing the tolerogenic molecules ILT2, ILT3,
retion profile of immature DCs and DC-10 left unstimulated (upper
e supernatants were collected after 48 hours and levels of cytokines
mature DCs differentiated by culturing monocytes with GM-CSF and
.
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DCs, or DC-10 promotes the induction of Tr1 cells;
however, at least three repetitive stimulations of naïve T
cells with immature DCs or IL-10 DCs are required to
induce suppressor Tr1 cells in vitro ([57] and S. Gregori,
personal communication), whereas only a single stimula-
tion of allogeneic naïve T cells with DC-10 is sufficient
to generate a population of T cells comprising up to 15%
of allo-specific Tr1 cells [59,60].
The high expression levels of ILT4, HLA-G, and IL-10
are necessary for the tolerogenic activity of DC-10 and
their ability to prime T cells to become Tr1 cells. Indeed,
addition of blocking antibodies against IL-10R, ILT4, or
HLA-G during co-culture of DC-10 and naïve T cells
completely prevented Tr1 cell induction [21]. This obser-
vation has been indirectly confirmed by studies in which
we compared the ability of G-CSF and IL-10 to promote
the induction of human tolerogenic DCs. G-CSF is a
modulator of T-cell and DC functions. Previous reports
showed that monocytes from G-CSF-treated healthy
donors differentiate into tolerogenic DCs in the presence
of autologous serum, which contains high levels of IL-10
and IFNα, and induce Tr1 cells in vitro [61]. This study
demonstrated that G-CSF indirectly modulates DC func-
tions. We recently defined a direct effect of G-CSF on
DCs. Addition of G-CSF and IL-4 during monocyte-
derived DC differentiation gives rise to a population of
cells (G-DCs) that express CD14 and CD16, but not
CD1a, display a mature myeloid phenotype, being HLA-
DR+CD80+CD83+CD86+, and express the tolerogenic
markers ILT4 and HLA-G [16], resembling the DC-10
phenotype. However, compared with DC-10, G-DCs pro-
duce lower levels of IL-10 and IL-6 if not stimulated, and
higher levels of IL-12 and TNFα upon stimulation; more-
over, G-DCs express significantly lower levels of HLA-G
and ILT4 compared with DC-10 (M. Rossetti and
S. Gregori, personal communication). Consistent with
these findings, G-DCs retain hypostimulatory capacity
but are not able to induce anergic and suppressive Tr1
cells [16].
DC-10 also differentiate Ag-specific Tr1 cells in
autologous settings. We demonstrated that DC-10 from
monocytes of allergic patients pulsed with allergen effi-
ciently promote the generation of allergen-specific Tr1
cells able to suppress cytokine production by effector
T-helper type 2 cells in vitro [58].
DC-10 are thus a population of tolerogenic DCs that
can be easily differentiated and can be used to promote
Ag-specific Tr1 cells in vitro.
Comparison between DC-10 and other regulatory
antigen-presenting cells under clinical development
Comparison between DC-10 and other regulatory APCs
described in the literature, and currently under clinicaldevelopment, indicates that DC-10 represent a popula-
tion of human tolerogenic DCs with a unique phenotype
and function (Figure 2). Despite the expression of CD14
and CD16, monocyte-derived DC-10 differ from human
type 2 macrophages (M2 cells) generated in vitro from
monocytes after exposure to M-CSF and IL-4 or IL-13,
or IL-10 [62-64] (Table 1). Both DC-10 and M2 cells se-
crete high levels of IL-10 and low amounts of IL-12, but
DC-10 produce IL-6, whereas M2 cells do not [62,64].
DC-10 are different from tolerogenic DCs generated
from nonhuman primate bone-marrow precursors with
GM-CSF (GM-CSF DCs) [65] (Table 1). GM-CSF DCs
have been extensively studied in nonhuman primates
and rodents [65,66]; more recently a protocol to gener-
ate these cells from human peripheral blood monocytes
has been developed (A. Moreau, The ONE Study Work-
shop, 2012). GM-CSF DCs are phenotypically different
from DC-10 since they are CD68+ adherent cells and do
not express DC-SIGN. Nonhuman primate and rodent
GM-CSF DCs display a cytokine production profile that
mirrors the one of DC-10, and express HO-1, a critical
molecule used by these cells to actively modulate im-
mune responses [66,73] (Figure 2). It still remains to be
determined whether GM-CSF DCs generated from
human peripheral blood monocytes are superimposable
to those obtained from nonhuman primate and rodent
bone-marrow precursors.
A protocol to differentiate human tolerogenic DCs
using RAPA has been recently developed by the group
of Angus W. Thomson ([67] and C. Macedo, The ONE
Study Workshop, 2012) (Table 1). Addition of RAPA
during monocyte-derived DC differentiation gives rise to
a population of DCs termed RAPA-DC that are CD1a
+CD14–, display an immature phenotype [32], and ex-
press low levels of the tolerogenic molecules ILT2, ILT3,
and ILT4 [68]; RAPA-DC are thereby phenotypically dif-
ferent from DC-10. Interestingly, it has been shown that
addition of RAPA at the beginning of DC differentiation
prevents the ability of resulting DCs to secrete IL-12
upon activation [74]. However, when RAPA is added
briefly before DC maturation, it inhibits IL-10 produc-
tion with the concomitant increase of IL-12 [74]. Similar
to DC-10, RAPA-DC weakly stimulate T cells and induce
T-cell hyporesponsiveness [32,33]. In contrast to DC-10,
however, RAPA-DC promote apopotosis of effector T
cells and expand FOXP3+ Tregs [74] (Figure 2).
Treatment of immature DCs with 1,25-dihydroxyvitamin
D3 in combination with IFNα upregulates the expression
of both ILT3 and ILT4, and downregulates co-stimulatory
molecules on resulting DCs, which, similarly to DC-10,
acquired the ability to generate suppressor T cells via ILTs
[75] (Table 1). Activation of immature DCs with 1,25-
dihydroxyvitamin D3 and dexamethasone also promotes
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Figure 2 Mechanisms of tolerance mediated by different tolerogenic antigen-presenting cells currently under clinical development.
DC-10 secrete IL-10 and upregulate the expression of immunoglobulin-like transcript (ILT) 4 and HLA-G molecules. During T-cell priming, ILT4/
HLA-G interaction promotes anergy in T cells, which become type 1 regulatory T (Tr1) cells. Granulocyte–macrophage colony-stimulating factor
(GM-CSF) dendritic cells (DCs) expressed heme oxygenase-1 (HO-1), which is involved in their mechanisms of action. It still remains to define
whether HO-1 expression promotes IL-10 production by GM-CSF DC and Tr1 cell differentiation. Myeloid-derived suppressor cells (MDSCs) express
indoleamine-2,3-dioxigenase (IDO) and induce T-helper type 2 skewing. Regulatory macrophages (M reg) are IDO+ and induce apoptosis of
effector T cells while sparing forkhead box P3 (FOXP3)+ regulatory T cells (Tregs). Rapamycin (RAPA) DCs promote FOXP3+ Tregs, but the
mechanism of induction is still under debate. 1,25-Dihydroxyvitamin D3/dexamethasone DCs promote suppressor T cells, but it is not clear
whether this is mediated by ILT4 expression and IL-10 secretion.
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and secrete high levels of IL-10 in the absence of IL-12
[69,70]. D3/Dexa-DC inhibit T-cell proliferation and
promote the induction of suppressor T cells (Figure 2).
Interestingly, it has been demonstrated that cytokine
polarization of naïve T cells into IL-10-producing T cells
and anergy induction by D3/Dexa-DC were reverted by
the addition of exogenous IL-12, whereas neutralization
of IL-10 had no effects [70]. The lack of IL-12, and
not the high levels of IL-10, is thus a key feature of
D3/Dexa-DC regulatory activity.
The group of Edward K. Geissler developed a clin-
ical grade protocol to generate human regulatory
macrophages (M reg) from monocytes cultured
with M-CSF and activated with IFNγ ([71] and J.A.
Hutchinson and P. Riquelme, The ONE StudyWorkshop, 2012) (Table 1). M reg are CD14–/
lowCD16–CD64+CD163–/lowHLA-DR+CD80–/lowCD86+
[71]. M-reg express IDO, which is involved in their
regulatory functions [72], and studies performed with
murine Mreg demonstrated that, when co-cultured
with T cells, they induce apoptosis of effector T cells,
while sparing FOXP3+ Tregs [76]. M-reg are thus
phenotypically and functionally different from DC-10
(Figure 2).
Differentiation of monocytes in the presence of GM-
CSF, IL-4, and prostaglandin E2 allows the induction of a
population of regulatory APCs, termed myeloid-derived
suppressor cells (MDSCs) ([26,28] and O. Natasa, The
ONE Study Workshop, 2012) (Table 1). Myeloid-derived
suppressor cells are CD1a– cells, display a mature pheno-
type, and secrete IL-10 but not IL-12 [26], and thus they














DC-10 CD14+ GM-CSF, No CD1aneg High IL-10high HLA-Ghigh IL-10 [21]
IL-4, ILT4high
IL-10 for 7d CD14 IL-12neg/low HLA-G
CD16 CD83 IL-6 ILT4
TNFαlow










for 6d CD14 MR
GM-CSF DC
(macaque)
CD14+ GM-CSF for 7d Yes CD68 High IL-10 HO-1 HO-1 [65,66]
BM CD14neg IL-12neg/low
RAPA-DC CD14+ GM-CSF, No CD68 Low IL-12+ IL-12 [67,68]
CD14negIL-4,
RAPA for 7d IL-10low
IL-6low








M reg CD14+ M-CSF Yes CD64+ HLA-DR+ IL-6low IDO IDO [71,72]
CD14neg/low
for 6d CD16neg CD80–/low IL-10neg
CD163neg/low TNF-αneg
+ IFNγ (o.n.) CD86+
MDSC CD14+ GM-CSF, No CD1aneg/low Low IL-10 IDO PGE2 [26,28]
TGF-βIL-4,
PGE2 for 6d CD14
+ Arginase,
COX2
APC, antigen-presenting cell; BM, Bone Marrow; COX2, cyclooxygenase-2; Dexa, dexamethasone; GM-CSF, granulocyte–macrophage colony-stimulating factor;
HO-1, heme oxygenase-1; IDO, indoleamine-2,3-dioxigenase; ILT, immunoglobulin-like transcript; LPS, lipopolysaccharide; M2 cell, human type 2 macrophage; M
reg, regulatory macrophage; M-CSF, macrophage colony-stimulating factor; MDSC, myeloid-derived suppressor cell; MR, mannose receptor; o.n., overnight; PGE2,
prostaglandin E2; RAPA, rapamycin; TGF-β, transforming growth factor beta; D3, 1,25-dihydroxyvitamin D3.
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of naïve T cells in the presence of MDSCs promotes the
induction of T-helper type 2 cells [77].
Overall, DC-10 share some similarities with other tol-
erogenic APCs but represent a unique subset of tolero-
genic DCs characterized by the co-expression of high
levels of ILT4 and HLA-G, with the distinct property of
inducing Tr1 cells via the IL-10-dependent ILT4/HLA-G
pathway.Clinical applications of tolerogenic DC-10
The identification of DC-10 as APCs that efficiently pro-
mote the induction of Tr1 cells in vitro prompted us to
develop an efficient and reproducible in vitro method to
generate, with minimal cell manipulation, allo-specific
Tr1 cells, using DC-10 [59,60]. Activation of allogeneic
T cells with DC-10 induces a population of alloAg-
specific T cells (IL-10-anergized T cells) containing Tr1
cells that are anergic and actively suppress alloAg-
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population. The protocol has been validated in good
manufacturing practice (GMP) conditions. A pilot clin-
ical trial for adoptive transfer of ex-vivo IL-10-anergized
Tr1 cells of donor origin using DC-10 (or monocytes +
IL-10; IL-10 DLI) has been completed in patients
affected by hematological malignancies, who underwent
T-cell-depleted haploidentical hematopoietic stem cell
transplantation (ALT-TEN protocol) [78,79]. In this clin-
ical setting, DC-10 in vitro differentiated from peripheral
monocytes of patients have been used to anergize donor
T cells. The goal of the trial was to provide immune re-
constitution without severe graft-versus-host disease in
the absence of immunosuppression. This first proof-of-
concept clinical trial demonstrated the safety and feasi-
bility of this approach. No acute adverse effects related
to IL-10-anergized donor T-cell infusion were observed;
however, rapid and long-term immune reconstitution to-
gether with absence of relapse were achieved [79]. The
IL-10 DLI cell therapy can be used for the treatment of
cancer patients and those with genetic hematologic dis-
eases in the need of allogeneic hematopoietic stem cell
transplantation, not only from haploidentical donors but
also from matched unrelated donors. Moreover, the cell
therapy protocol with IL-10-anergized Tr1 cells can be
extended to prevent rejection after organ transplants. In
this case, DC-10 in vitro differentiated from donor
monocytes will be used to anergize recipient T cells.
This cell product has been selected to be a part of The
ONE Study, an integrated European Union-funded
project, led by Edward K. Geissler in Regensburg
(Germany). This cooperative project aims at developing
and testing different subsets of regulatory cell products
in kidney-transplanted recipients, allowing a direct com-
parison of the safety, clinical practicality and therapeutic
efficacy of each cell type [80,81].
Ag-specific IL-10-anergized Tr1 cells can be induced
with autologous DC-10 pulsed with a given antigen [58],
thereby DC-10-derived Tr1 cells can be used as a cell
product for restoring tolerance in autoimmune diseases.
Alternative to the use of DC-10 as inducers of Ag-
specific Tr1 cells for tailoring Treg-based cell therapy,
DC-10 represent an interesting therapeutic tool for DC-
based cell therapy promoting and restoring tolerance in
T-cell-mediated diseases. The challenge for the adoptive
DC therapy is to generate tolerogenic DCs with a stable
phenotype, which are resistant to maturation mediated
by proinflammatory mediators. Recently, a comparative
analysis of GMP protocols to generate human tolero-
genic DCs using IL-10, TGFβ, 1,25-dihydroxyvitamin D3,
dexamethasone or RAPA showed that IL-10 DCs are the
most stable cell product. Based on these results the
authors suggested that IL-10 DCs are the best suitable
subset of tolerogenic DCs for tolerance-inducingtherapies [82]. We showed that DC-10 are phenotypic-
ally stable cells and are functionally more efficient than
IL-10 DCs in promoting Ag-specific Tr1 cells in vitro
(S. Gregori and D. Tomasoni, personal communication),
thereby representing a good candidate for cell-therapy
approaches. In this scenario, the use of allogeneic DC-10
or autologous DC-10 pulsed with a given Ag can be pre-
dicted to prevent graft rejection or restore tolerance in
T-cell-mediated diseases, such as autoimmune diseases
and allergy.
Conclusions and perspectives
Since their discovery, DCs have proved to play a central
role in regulating immune responses. Moreover, signifi-
cant advances have been made in establishing methods
to manipulate DCs in vitro to generate tolerogenic DCs
suitable for clinical applications. In this scenario, DC-10
are a good candidate since they can be easily differen-
tiated in vitro from monocyte precursors, and are stable
cells with potent suppressive functions. A protocol to
generate Ag-specific Tr1 cells by DC-10 for adoptive
Treg-based cell therapy has been developed and vali-
dated in GMP for clinical purposes. Moreover, DC-10
are of great potential interest as a therapeutic tool per se
to induce or re-establish immunological tolerance in dif-
ferent clinical settings including allogeneic transplant-
ation or autoimmune diseases. The manufacturing
protocol for GMP production of DC-10 is under devel-
opment. Further studies in humanized mouse models
and in large animal models are warranted to establish
the best route and dose of administration, lifespan and
homing kinetics of DC-10, in order to design clinical
protocols to test the safety and efficacy of DC-10-based
cell therapy.
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